[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Tabassum et al., 2017 - Google Patents

Analytical method development and validation studies of ticagrelor tablets by RP-HPLC

Tabassum et al., 2017

View PDF
Document ID
1449028914872948443
Author
Tabassum K
Sarvesh R
Publication year
Publication venue
International Journal of Applied Pharmaceutics

External Links

Snippet

Objective: The present study was conducted to develop a simple and precise analytical method for the estimation of ticagrelor in tablet formulation. Methods: Reverse Phase HPLC was used for method development and validation studies of ticagrelor. The optimum …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
    • G01N30/94—Development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Similar Documents

Publication Publication Date Title
Daraghmeh et al. Determinaton of sildenafil citrate and related substances in the commercial products and tablet dosage form using HPLC
Kubica et al. Modern approach for determination of lactulose, mannitol and sucrose in human urine using HPLC–MS/MS for the studies of intestinal and upper digestive tract permeability
Tabassum et al. Analytical method development and validation studies of ticagrelor tablets by RP-HPLC
Elkady et al. Validated liquid chromatographic method for simultaneous determination of metformin, pioglitazone, sitagliptin, repaglinide, glibenclamide and gliclazide-application for counterfeit drug analysis
Ibrahim et al. Sensitive inexpensive HPLC determination of four antiepileptic drugs in human plasma: application to PK studies
Abdallah HPLC and densitometric TLC methods for simultaneous determination of gemifloxacin with some co-administered drugs in human plasma
Chaudhari et al. Stability-indicating reversed-phase liquid chromatographic method for simultaneous determination of simvastatin and ezetimibe from their combination drug products
Klausz et al. Simultaneous determination of praziquantel, pyrantel embonate, febantel and its active metabolites, oxfendazole and fenbendazole, in dog plasma by liquid chromatography/mass spectrometry
Bende et al. UV-spectrophotometric determination of imatinib mesylate and its application in solubility studies
Yasir et al. Development of UV spectrophotometric method for the analysis of acetylcholinesterase inhibitor
Banaszkiewicz et al. Determination of benzodiazepines and Z-hypnotic drugs in whole blood samples by GC–MS/MS: method development, validation and application
Gupta et al. Method development and acid degradation study of doxofylline by RP-HPLC and LC-MS/MS
Patil et al. Stability indicating LC method for the simultaneous determination of amlodipine and olmesartan in dosage form
Prajapati et al. SFC-MS for the identification and estimation of ethambutol in its dosage form and in human urine samples
Ibrahim et al. Fast simultaneous quantitation of valsartan and amlodipine besylate using an eco-friendly micellar HPLC-UV method: application to spiked human plasma and content uniformity testing for amlodipine
Kim Development of an Ion‐Pairing Reagent and HPLC‐UV Method for the Detection and Quantification of Six Water‐Soluble Vitamins in Animal Feed
Belal et al. Application of liquid chromatographic method with fluorescence detection for the determination of triclabendazole in tablets and biological fluids
Sharma et al. Method development and validation of dual wavelength UV spectrophotometric method for simultaneous estimation of paracetamol and caffeine in combined dosage form by internal standard method
Al-Ani et al. Development and validation of stability indicating RP-HPLC method of apixaban in commercial dosage forms
Gupta et al. Method Development and Photolytic Degradation Study of Doxofylline by RP-HPLC and LC-MS/MS
Woo et al. Quantitative determination of voglibose in pharmaceutical tablets using high-performance liquid chromatography–fluorescence detection with post-column derivatization and mass spectrometric detection
Damodar et al. RP-HPLC Method Development and Validation for the Analyisis of Lurasidone in Pharmaceutical Dosage Forms
Yaman et al. Optimization of HPLC-FLD conditions using analytical quality by design approach for quantification of silodosin in pharmaceutical dosage form
SHARMA et al. A validated gradient stability-indicating LC method for the analysis of valsartan in pharmaceutical dosage form
Erk et al. Comparison of derivative spectrophotometric and liquid chromatographic methods for the determination of rofecoxib